58 results on '"Jeger, Raban V"'
Search Results
2. Rest in PEACE?
3. Impact of the COVID-19 Pandemic on Global TAVR Activity
4. Association of chocolate consumption with neurological and cardiovascular outcomes in atrial fibrillation: data from two Swiss atrial fibrillation cohort studies (Swiss-AF and BEAT-AF)
5. Impact of chronic kidney disease and diabetes on clinical outcomes in women undergoing PCI
6. Drug-Coated Balloons in Multivessel Coronary Artery Disease
7. Value of Periprocedural Electrophysiology Testing During Transcatheter Aortic Valve Replacement for Risk Stratification of Patients With New‐Onset Left Bundle‐Branch Block
8. First-in-man concomitant mitral valve replacement and coronary artery bypass grafting using a single minimally invasive access
9. IMPACT OF CORONARY ARTERY DISEASE ON CLINICAL OUTCOMES AFTER TAVR: INSIGHTS FROM THE BRAVO-3 RANDOMIZED TRIAL
10. IMPACT OF CHRONIC THROMBOCYTOPENIA ON CLINICAL OUTCOMES AFTER TAVR: INSIGHTS FROM THE BRAVO-3 RANDOMIZED TRIAL
11. Drug-coated balloons for small coronary artery disease in patients with chronic kidney disease: a pre-specified analysis of the BASKET-SMALL 2 trial
12. Impact of Diabetes on Outcome With Drug-Coated Balloons Versus Drug-Eluting Stents
13. Transcatheter Aortic Valve Replacement With the LOTUS Edge System
14. Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial
15. Drug-Coated Balloons for Coronary Artery Disease
16. Sex-Specific Management in Patients With Acute Myocardial Infarction and Cardiogenic Shock
17. Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement
18. Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents
19. Drug-coated balloons: room for development of BASKET-SMALL 2 – Authors' reply
20. Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II
21. Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial
22. Stents in saphenous vein grafts
23. Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents
24. Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents
25. Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction
26. Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents
27. Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization
28. Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis
29. Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents
30. Abstract 18702: Obesity Paradox in Women Undergoing Percutaneous Coronary Intervention With Drug-eluting Stents: Results From a Patient-level Pooled Analysis of Randomized Controlled Trials
31. Letter by Jeger and Pfisterer Regarding Article, “Prasugrel Plus Aspirin Beyond 12 Months Is Associated With Improved Outcomes After TAXUS Liberté Paclitaxel-Eluting Coronary Stent Placement”
32. Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or Non–ST-Elevation Myocardial Infarction vs ST-Elevation Myocardial Infarction) on Long-Term Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents
33. Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations
34. Prognostic Value of “Routine” Cardiac Stress Imaging 5 Years After Percutaneous Coronary Intervention
35. First-in-man Portico® transcatheter aortic valve-in-valve implantation in a degenerated 19 mm Mitroflow® aortic pericardial heart valve
36. Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials
37. Mens sana in corpore sano revisited
38. By a Hair’s Breadth
39. Stent Thrombosis after Coronary Stent Implantation: A Protective Effect of High-Dose Statin Therapy?
40. Early revascularization is beneficial across all ages and a wide spectrum of cardiogenic shock severity: A pooled analysis of trials
41. Drug-eluting stents and glycoprotein IIb/IIIa inhibitors in vessels at low anatomic risk: A retrospective analysis of previously published data from the Basel Stent Kosten Effektivitäts Trial
42. Ischaemic mitral regurgitation
43. Drug-Eluting Stents Compared with Bare Metal Stents Improve Late Outcome after Saphenous Vein Graft but Not after Large Native Vessel Interventions
44. Outpatient Rehabilitation in Patients With Coronary Artery and Peripheral Arterial Occlusive Disease
45. Hemodynamic Parameters Are Prognostically Important in Cardiogenic Shock But Similar Following Early Revascularization or Initial Medical Stabilization
46. Oral Hypoglycemics: Increased Postoperative Mortality in Coronary Risk Patients
47. Causes of death and re‐hospitalization in cardiogenic shock
48. Interhospital transfer for early revascularization in patients with ST-elevation myocardial infarction complicated by cardiogenic shock—a report from the SHould we revascularize Occluded Coronaries for cardiogenic shocK? (SHOCK) trial and registry
49. Long-term prognostic value of the preoperative 12-lead electrocardiogram before major noncardiac surgery in coronary artery disease
50. Emergency revascularization in patients with cardiogenic shock on admission: a report from the SHOCK trial and registry
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.